401k Record

Employers › CutisPharma

CutisPharma 401(k)

Recordkeeping fees per participant · Azurity Pharmaceutical, Inc. 401(k) Profit Sharing Plan Trust · plan year 2024

$130.10

Higher than 85% of the 5,847 plans $50 to 250M that report it.

Source

= $104,211 / 801
Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251011053606NAL0019481730001, received 2025-10-11
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011053606NAL0019481730001, received 2025-10-11

10th: $10.22median $69.9190th: $151.08

Percentiles compare this plan with the Schedule H plans $50 to 250M in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-10-11.

Cost and contributions

Administrative expenses excluding investment management, per participant

$130.10

10th: $16.21median $93.2090th: $246.84

Higher than 68% of the 8,758 plans $50 to 250M that report it.

Source

= $104,211 / 801
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251011053606NAL0019481730001, received 2025-10-11
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011053606NAL0019481730001, received 2025-10-11

Administrative expenses per participant

$192.57

10th: $29.39median $132.8490th: $350.58

Higher than 69% of the 9,042 plans $50 to 250M that report it.

Source

= $154,245 / 801
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251011053606NAL0019481730001, received 2025-10-11
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011053606NAL0019481730001, received 2025-10-11

Administrative expenses as a share of assets

0.245%

10th: 0.022%median 0.136%90th: 0.326%

Higher than 79% of the 9,049 plans $50 to 250M that report it.

Source

= $154,245 / $62,904,977
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251011053606NAL0019481730001, received 2025-10-11
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251011053606NAL0019481730001, received 2025-10-11

Employer contributions per participant

$3,797

10th: $965median $2,73890th: $8,164

Higher than 66% of the 9,105 plans $50 to 250M that report it.

Source

= $3,041,668 / 801
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251011053606NAL0019481730001, received 2025-10-11
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011053606NAL0019481730001, received 2025-10-11

Employer share of total contributions

27.4%

10th: 15.6%median 29.5%90th: 50.6%

Higher than 42% of the 9,112 plans $50 to 250M that report it.

Source

= $3,041,668 / $11,115,991
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251011053606NAL0019481730001, received 2025-10-11
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251011053606NAL0019481730001, received 2025-10-11

Plan terms, as stated in CutisPharma, Inc.'s SEC filings

Plan terms are not published in public filings.

Plan features

2E profit-sharing · 2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2S pre-approved plan document · 2T default investment (QDIA) · 3D IRS pre-approved plan · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20251011053606NAL0019481730001, received 2025-10-11

Full record, Azurity Pharmaceutical, Inc. 401(k) Profit Sharing Plan Trust

FieldValueSource
Plan sponsorAZURITY PHARMACEUTICALS, INC.Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20251011053606NAL0019481730001, received 2025-10-11
Plan nameAZURITY PHARMACEUTICAL, INC. 401(K) PROFIT SHARING PLAN TRUSTForm 5500, line 1a; PLAN_NAME pos 16; filing 20251011053606NAL0019481730001, received 2025-10-11
Sponsor EIN / plan number04-3450615 / 001Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20251011053606NAL0019481730001, received 2025-10-11
Plan typesingle-employerForm 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20251011053606NAL0019481730001, received 2025-10-11
Sponsor locationWOBURN, MAForm 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20251011053606NAL0019481730001, received 2025-10-11
Industry (business code)621510, Health care and social assistanceForm 5500, line 2d; BUSINESS_CODE pos 46; filing 20251011053606NAL0019481730001, received 2025-10-11
Plan year2024-01-01 to 2024-12-31Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20251011053606NAL0019481730001, received 2025-10-11
Filing received2025-10-11Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20251011053606NAL0019481730001, received 2025-10-11
Final filingnoForm 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20251011053606NAL0019481730001, received 2025-10-11
Amended filingnoForm 5500, Part I line B; AMENDED_IND pos 7; filing 20251011053606NAL0019481730001, received 2025-10-11
Participants, beginning of year852Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20251011053606NAL0019481730001, received 2025-10-11
Active participants389Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20251011053606NAL0019481730001, received 2025-10-11
Participants, end of year811Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20251011053606NAL0019481730001, received 2025-10-11
Participants with an account balance801Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011053606NAL0019481730001, received 2025-10-11
Total assets, beginning of year$51,851,279Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20251011053606NAL0019481730001, received 2025-10-11
Total assets, end of year$62,904,977Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251011053606NAL0019481730001, received 2025-10-11
Net assets, end of year$62,904,977Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20251011053606NAL0019481730001, received 2025-10-11
Total income$19,096,896Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20251011053606NAL0019481730001, received 2025-10-11
Net income$9,377,238Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20251011053606NAL0019481730001, received 2025-10-11
Employer contributions$3,041,668Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251011053606NAL0019481730001, received 2025-10-11
Participant contributions$6,051,422Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20251011053606NAL0019481730001, received 2025-10-11
Other contributions (incl. rollovers)$2,022,901Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20251011053606NAL0019481730001, received 2025-10-11
Total contributions$11,115,991Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251011053606NAL0019481730001, received 2025-10-11
Benefit payments$9,488,713Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20251011053606NAL0019481730001, received 2025-10-11
Total expenses (incl. benefit payments)$9,719,658Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20251011053606NAL0019481730001, received 2025-10-11
Total administrative expenses$154,245Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251011053606NAL0019481730001, received 2025-10-11
Recordkeeping fees$104,211Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251011053606NAL0019481730001, received 2025-10-11
Investment advisory and management fees$50,034Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20251011053606NAL0019481730001, received 2025-10-11
Administrative expenses excluding investment management$104,211derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251011053606NAL0019481730001, received 2025-10-11
Held in mutual funds$62,165,721Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20251011053606NAL0019481730001, received 2025-10-11
Independent auditorCOHNREZNICK LLPSchedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20251011053606NAL0019481730001, received 2025-10-11

Position = column in the DOL layout for form year 2024. Filing 20251011053606NAL0019481730001, received 2025-10-11.

Service providers paid directly by the plan

ProviderRelationshipService codesDirect compensationIndirect
ADP, INC.recordkeeperRECORD KEEPER 37 Participant loan processing; 50 Direct payment from the plan; 15 Recordkeeping and information management; 64 Recordkeeping fees; 26 Investment advisory (participants); 49 Other services; 99 Other fees $104,211yes
GLOBAL RETIREMENT PARTNERSrecordkeeperINVESTMENT/FINANCIAL ADVI 15 Recordkeeping and information management; 21 Trustee (bank, trust company or similar); 49 Other services; 50 Direct payment from the plan; 64 Recordkeeping fees; 99 Other fees $50,034no

Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20251011053606NAL0019481730001, received 2025-10-11.

What changed since the 2023 plan year

Figure20232024Change
Total assets$51,851,279$62,904,97721.3%
Participants with a balance811801-1.2%
Administrative expenses$169,999$154,245-9.3%
Recordkeeping fees per participant$71.86$130.1081.1%
Employer contributions$1,209,483$3,041,668151.5%

Prior filing 20241101094143NAL0001864403001, received 2024-11-01; the plan years are contiguous.

Alerts, claims and corrections

Alert me when this filing changes

One email when a new Form 5500 for Azurity Pharmaceutical, Inc. 401(k) Profit Sharing Plan Trust appears in the Department of Labor data. Confirmation link first; unsubscribe link in every email.

Claim this plan

For the sponsor or its plan administrator: request to verify or annotate this page. A work email address at the sponsor speeds up verification.

Report a correction

Every figure is reproduced from the filing with its source. Tell us which figure and what the filing says instead.

Sponsor name as filed: AZURITY PHARMACEUTICALS, INC.; SEC registrant: CutisPharma, Inc. (CIK 1628863, matched by EIN).